Open access
EMPAGLIFLOZIN AND DAPAGLIFLOZIN IN IMPROVING EJECTION FRACTION: A PROSPECTIVE OBSERVATIONAL COMPARISON OF CLINICAL OUTCOMES AND PATIENT REPORTED QUALITY OF LIFE
C. Bhargava
M. Daisy
Joyce Sharon
Alavala Lakshmi Lahari
Akumalla Gowtham
Shaik Abdul Sameer
Ambati Sandeep Reddy
Nishitha Reddy
Ambati Sandeep
Reddy
Abstract
Background: SGLT2 inhibitors have transformed heart failure treatment, especially empagliflozin and dapagliflozin. Although both have proven cardiovascular benefits in clinical trials, there is little data comparing them in real-world settings. This study aims to address that by comparing their effects on heart function, lab tests, echocardiography